Vikrant Vijay Data-verified

Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.

Staff Fellow (Pharmacologist)

NCTR

Last publication 2026 Last refreshed 2026-05-16

staff

16 h-index 45 pubs 1,177 cited

Research Areas

Links

ORCID Research Group

OverviewAI-generated summary

Vikrant Vijay's research focuses on understanding and predicting drug-induced toxicities, particularly cardiotoxicity. His work investigates the molecular mechanisms underlying these adverse effects, employing techniques such as gene expression profiling and metabolomics. A significant portion of his research has examined the cardiotoxic effects of doxorubicin, an antineoplastic antibiotic, in mouse models. He has explored delayed-onset cardiotoxicity and the potential role of specific pathways, like the apelin-APJ pathway, in sex-related differential toxicity. Vijay has also identified circulating microRNAs as potential early biomarkers for chronic cardiotoxicity. His research extends to the development of frameworks for integrating transcriptomics and metabolomics data in regulatory toxicology and has explored metabolomics for identifying biomarkers in COVID-19 patient plasma. Collaborations include work with researchers from the National Center for Toxicological Research and the University of Arkansas for Medical Sciences.

Metrics

h-index: 16
Publications: 45
Citations: 1,177

Selected Publications

Correction: Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study (2026)

DOI OpenAlex
Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study (2025)

DOI OpenAlex
Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals disease severity biomarkers (2024)

4 citations DOI OpenAlex
Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin (2024)

3 citations DOI OpenAlex
Potential role of the apelin‐APJ pathway in sex‐related differential cardiotoxicity induced by doxorubicin in mice (2022)

4 citations DOI OpenAlex
MicroRNA‐34a‐5p as a promising early circulating preclinical biomarker of doxorubicin‐induced chronic cardiotoxicity (2022)

13 citations DOI OpenAlex
Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice (2021)

14 citations DOI OpenAlex
Progress towards an OECD reporting framework for transcriptomics and metabolomics in regulatory toxicology (2021)

89 citations DOI OpenAlex